论文部分内容阅读
目的观察氟哌噻吨美利曲辛联合右佐匹克隆治疗老年失眠伴发抑郁和(或)焦虑状态的疗效及安全性。方法选取2014年3月—2016年5月就诊的老年失眠症患者136例。按随机数字表法分为对照组(62例)和研究组(74例)。对照组采用氟哌噻吨美利曲辛片治疗,研究组采用右佐匹克隆联合氟哌噻吨美利曲辛片治疗。对比两组HAMA、HAMD、PSQI评分和TESS量表。计量资料比较采用t检验,计数资料比较采用χ~2检验,P<0.05为差异有统计学意义。结果两组治疗后HAMA、HAMD评分比较,差异无统计学意义(均P>0.05);两组治疗后PSQI评分比较,差异有统计学意义(P<0.05);两组治疗前、治疗后2周及治疗后8周TESS评分比较,差异无统计学意义(均P>0.05)。结论右佐匹克隆联合氟哌噻吨美利曲辛疗效治疗老年失眠伴焦虑和(或)抑郁效果显著,且安全性高,无明显毒副作用。
Objective To observe the efficacy and safety of flupenthixol combined with melitracen and dexrazoxane in the treatment of senile insomnia with depression and / or anxiety. Methods 136 elderly patients with insomnia were selected from March 2014 to May 2016. According to random number table divided into control group (62 cases) and study group (74 cases). The control group was treated with flupentixol and melitracen tablets. The study group was treated with dexrazoxane and flupentixol and melitracen tablets. HAMA, HAMD, PSQI scores and TESS scale were compared between two groups. Measurement data were compared using t test, count data were compared using χ ~ 2 test, P <0.05 for the difference was statistically significant. Results There was no significant difference in HAMA and HAMD scores between the two groups after treatment (all P> 0.05). There was significant difference in PSQI score between the two groups after treatment (P <0.05) There was no significant difference in the TESS score between weeks and 8 weeks after treatment (all P> 0.05). Conclusion The combination of dexrazoxane and flupentixol and melitracen can effectively relieve the anxiety and / or depression of senile insomnia with high safety and no obvious side effects.